Royal London Hospital for Integrated Medicine
London, WC1N 3HR, United Kingdom
NCT Number: NCT06716944
Patients who have had a course of acupuncture at the Royal London Hospital for Integrated Medicine to manage their migraines, and found it effective, will be taught to do self-acupuncture. This is a feasibility study so the main aim is to test the trial design but the researchers will also explore self-acupuncture's effectiveness, acceptability and safety.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1 / Phase 2
London, WC1N 3HR, United Kingdom
Aim: The proposed study will evaluate the feasibility of teaching SA to patients with migraines in the United Kingdom National Health Service setting.
Methodology: The study will employ a pragmatic, mixed-methods, randomised, parallel-group, exploratory design. The study will compare SA plus standard care versus standard care alone. Participants will complete outcome measures at various time points and be invited to take part in a qualitative telephone interview to explore their views on the design of the study and acceptability of the intervention. The researcher will take field notes of the observation of the SA teaching session to explore the acceptability of the SA teaching method. Data will be analysed to test the hypothesis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
self-acupuncture
Time frame: From enrolment to end of intervention at 24 weeks
HIT-6 assesses the burden of headaches (including migraine) by assessing the impact of headaches on peoples' daily living, work and social situations. Patients rate six areas of potential impact on a 5-part scale from 'never' to 'always'.
Time frame: From enrolment to end of intervention at 24 weeks
MIDAS assesses the impact headaches or migraines have on peoples' daily living. Patients record the number of days in the last three months that their migraine has impacted their work, household work and social activities (there are five items in the measure).
Time frame: From enrolment to end of intervention at 24 weeks
MSQ v2.1 assesses the impact of migraine on peoples' quality of life. Patients rate how often in the last four weeks their migraine has impacted various areas of daily living. The questionnaire consists of 14 questions which relate to three areas: daily activities the patient was restricted from doing, daily activities the patient was prevented from doing and impact on emotional wellbeing. Patients can rate the impact of each item on a 6-part scale from 'none of the time' to 'all of the time'.
Time frame: From enrolment to end of intervention at 24 weeks
The PCS measures the impact of pain on peoples' daily living. The questionnaire consists of 13 items. Patients rate the impact pain has on these items on a 5-part scale from 'not at all' to 'all of the time'.
Time frame: From enrolment to end of intervention at 24 weeks
Participants will be asked to keep a diary of their migraines. They will be asked to record the frequency, duration and severity of their migraines, other symptoms they experienced (such as dizziness or nausea), any migraine or pain medication they took and any other comments.
University of West London
Other
A Feasibility Trial of Self-Acupuncture for Patients With Migraines (SAM)
Acronym: SAM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07297901
Autonomic Nervous System, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07698249
Brain Diseases, Central Nervous System Diseases
Edison, New Jersey, United States
View Trial DetailsNCT05755945
Brain Diseases, Central Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT07514208
Brain Diseases, Central Nervous System Diseases
Barcelona, Spain
View Trial Details